Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Melvin Berger

Showing results (1-10 of 63) with videos related to

Pageof 7
Sort By:
Clinical Immunology (Orlando, Fla.)|March 12, 2011
Another new mechanism of action of IGIVMelvin Berger
Journal of Clinical Immunology|October 3, 2007
A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of FlebogammaMelvin Berger,
Current Opinion in Allergy and Clinical Immunology|October 6, 2011
Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal doseMelvin Berger
Journal of Clinical Immunology|June 7, 2011
Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDDMelvin Berger
Clinical Immunology (Orlando, Fla.)|December 15, 2004
Why HAE?Melvin Berger
Immunology and Allergy Clinics of North America|April 22, 2008
Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiencyMelvin Berger
Transfusion|December 12, 2018
Antibodies to vaccine antigens in pooled polyclonal human IgG productsMelvin Berger
Immunotherapy|December 18, 2013
Subcutaneous IgG in neurologic diseasesMelvin Berger
Immunotherapy|February 17, 2011
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous useMelvin Berger
American Journal of Respiratory and Critical Care Medicine|April 6, 2002
Lung inflammation early in cystic fibrosis: bugs are indicted, but the defense is guiltyMelvin Berger
Pageof 7

Showing results (1-10 of 63) with videos related to

Sort By:
Pageof 7
Clinical Immunology (Orlando, Fla.)|March 12, 2011
Another new mechanism of action of IGIVMelvin Berger
Journal of Clinical Immunology|October 3, 2007
A multicenter, prospective, open label, historically controlled clinical trial to evaluate efficacy and safety in primary immunodeficiency diseases (PID) patients of Flebogamma 5% DIF, the next generation of FlebogammaMelvin Berger,
Current Opinion in Allergy and Clinical Immunology|October 6, 2011
Choices in IgG replacement therapy for primary immune deficiency diseases: subcutaneous IgG vs. intravenous IgG and selecting an optimal doseMelvin Berger
Journal of Clinical Immunology|June 7, 2011
Incidence of infection is inversely related to steady-state (trough) serum IgG level in studies of subcutaneous IgG in PIDDMelvin Berger
Clinical Immunology (Orlando, Fla.)|December 15, 2004
Why HAE?Melvin Berger
Immunology and Allergy Clinics of North America|April 22, 2008
Principles of and advances in immunoglobulin replacement therapy for primary immunodeficiencyMelvin Berger
Transfusion|December 12, 2018
Antibodies to vaccine antigens in pooled polyclonal human IgG productsMelvin Berger
Immunotherapy|December 18, 2013
Subcutaneous IgG in neurologic diseasesMelvin Berger
Immunotherapy|February 17, 2011
L-proline-stabilized human IgG: Privigen® 10% for intravenous use and Hizentra® 20% for subcutaneous useMelvin Berger
American Journal of Respiratory and Critical Care Medicine|April 6, 2002
Lung inflammation early in cystic fibrosis: bugs are indicted, but the defense is guiltyMelvin Berger
Pageof 7